MedImmune : Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13

April 15, 2008 - MedImmune announced that it has advanced its efforts to develop CAT-354, a potential treatment for patients with asthma, with the start of two new trials with a monoclonal antibody (MAb) targeting interleukin-13 (IL-13). One of the studies is a Phase 2 clinical trial in Europe and Australia designed to assess the potential of the anti-IL-13 MAb in patients with uncontrolled asthma despite optimal treatment. The company has also begun dosing patients in the first U.S.-based clinical trial of the antibody, a Phase 1 study to assess pharmacokinetics in healthy adult patients... MedImmune's Press Release -